ABOS · XBRL financial data

Acumen Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ABOS's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Research and development	13,293*	12,449	19,533	27,247	34,569*	25,266	37,125	21,968	20,526*	16,484	27,809	21,113
General and administrative	5,193*	5,325	4,848	5,018	5,028*	5,104	4,625	4,545	4,673*	4,665	4,747	4,700
Total operating expenses	18,486*	17,774	24,381	32,265	39,597*	30,370	41,750	26,513	25,199*	21,149	32,556	25,813
Operating income (loss)	(18,486)*	(17,774)	(24,381)	(32,265)	(39,597)*	(30,370)	(41,750)	(26,513)	(25,199)*	(21,149)	(32,556)	(25,813)
Interest income	3,951*	4,005	3,816	3,504	2,992*	2,471	2,015	1,639	1,322*	1,064	1,111	812
Interest expense	581*	1,000	1,004	1,027	1,037*	1,023	1,046	1,068	1,087*	1,069	1,094	999
Other income (expense)	(21)*	(54)	(68)	33	(62)*	(64)	(129)	(69)	(4)*	(43)	(19)	(19)
Income tax expense (benefit)	year only	—	—	—	year only	—	—	—	year only	—	—	—
Net income (loss)	(16,497)*	(14,873)	(20,537)	(29,765)	(37,154)*	(28,796)	(40,950)	(26,451)	(25,138)*	(20,737)	(32,718)	(25,369)
Earnings per share, basic USD per share	(0.28)*	(0.25)	(0.34)	(0.50)	(0.62)*	(0.48)	(0.68)	(0.44)	(0.41)*	(0.33)	(0.45)	(0.35)
Earnings per share, diluted USD per share	(0.28)*	(0.25)	(0.34)	(0.50)	(0.62)*	(0.48)	(0.68)	(0.44)	(0.41)*	(0.33)	(0.45)	(0.35)
Weighted average shares, basic thousands of shares	57,910*	59,812	60,080	60,080	60,080*	60,526	60,573	60,573	60,574*	63,219	72,251	72,321
Weighted average shares, diluted thousands of shares	57,910*	59,812	60,080	60,080	60,080*	60,526	60,573	60,573	60,574*	63,219	72,251	72,321

Balance sheet

CSV

Fiscal quarters (ABOS's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	66,886	46,930	67,955	33,184	35,627	30,159	36,810	46,832	53,989	51,796	59,443	53,075
Marketable securities	176,636	205,582	192,517	167,159	135,930	118,989	106,559	79,777	62,876	76,602	50,754	25,529
Marketable securities, non-current	62,553	44,108	20,908	58,552	59,968	48,795	22,797	9,443	0	—	—	—
Prepaid and other current assets	3,093	3,319	6,443	7,289	6,749	5,799	5,035	5,544	5,387	4,696	5,316	6,530
Total current assets	246,615	255,831	266,915	207,632	178,306	154,947	148,404	132,153	122,252	133,094	115,513	85,134
Property and equipment, net	122	117	105	89	73	137	130	115	103	91	80	68
Right-of-use asset	381	353	325	296	266	236	205	173	140	106	72	36
Total assets	310,125	300,967	288,913	266,975	238,992	204,478	171,897	142,221	122,833	133,629	116,007	85,565
Accounts payable	1,379	3,079	4,211	2,342	5,648	1,056	2,103	682	554	1,655	13,379	6,056
Accrued liabilities	6,339	2,905	4,004	4,926	6,615	6,711	11,650	7,792	10,072	5,268	7,533	10,168
Total current liabilities	12,971	8,472	15,367	19,914	27,607	19,315	24,861	21,956	30,007	29,229	46,848	45,087
Lease liability, non-current	284	252	219	185	150	114	77	39	—	—	—	—
Total liabilities	43,152	38,933	44,966	49,773	57,176	48,957	54,820	49,048	52,403	46,153	58,744	50,955
Accumulated deficit	(222,798)	(237,671)	(258,208)	(287,973)	(325,127)	(353,923)	(394,873)	(421,324)	(446,462)	(467,199)	(499,917)	(525,286)
Total stockholders' equity	266,973	262,034	243,947	217,202	181,816	155,521	117,077	93,173	70,430	87,476	57,263	34,610
Total liabilities and equity	310,125	300,967	288,913	266,975	238,992	204,478	171,897	142,221	122,833	133,629	116,007	85,565
Common shares outstanding (cover page) thousands of shares	60,080	60,080	60,080	60,080	60,573	60,573	60,573	60,573	72,213	72,228	72,317	72,327

Cash flows

CSV

Fiscal quarters (ABOS's year ends in late December)

In thousands of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(16,497)*	(14,873)	(20,537)	(29,765)	(37,154)*	(28,796)	(40,950)	(26,451)	(25,138)*	(20,737)	(32,718)	(25,369)
Stock-based compensation	1,634*	2,484	2,470*	2,338*	2,343*	2,474	2,498*	2,461*	2,419*	2,396	2,524*	2,706*
Net cash from operating activities	(8,314)*	(17,859)	(16,545)*	(24,596)*	(27,215)*	(34,121)	(31,832)*	(30,489)*	(19,096)*	(24,128)	(18,075)*	(26,653)*
Net cash from investing activities	(48,807)*	(9,203)	37,699*	(10,132)*	29,663*	28,689	38,483*	40,511*	26,250*	(13,807)	26,000*	25,250*
Proceeds from issuing common stock	(390)*	7,938	0*	0*	0*	0	0*	0*	0*	—	—	—
Net cash from financing activities	29,134*	7,107	(128)*	(42)*	(9)*	(36)	0*	0*	2*	35,742	(278)*	(4,965)*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Acumen Pharmaceuticals	53,075	not reported	(26,653)*	72.3M	3.4 quarters	Q3 FY26 10-QSep 30, 2026
Opus Genetics	88,812	755	(11,950)*	83.2M	7.4 quarters	Q2 FY26 10-QJun 30, 2026
Fortress Biotech	196,576	18,718	(59,277)*	33.3M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Actinium Pharmaceuticals	36,473	35,000	(5,179)*	31.4M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Precision Biosciences	81,698	0	(15,132)*	27.9M	6.1 quarters	Q3 FY26 10-QSep 30, 2026
Lite Strategy	5,706	not reported	(1,164)*	30.4M	4.9 quarters	Q4 FY26 10-KJun 30, 2026
Actuate Therapeutics	4,426	not reported	(4,405)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026
Fitlife Brands	1,089	not reported	3,635*	9.4M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.